Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Oryctolagus cuniculus | Angiotensin II type 1a (AT-1a) receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Angiotensin II type 2 (AT-2) receptor | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Duration (functional) | = 2.4 hr | Time from onset of action until significant (i.e., >=30%) inhibition of pressor response is no longer observed, at 1 (mg/kg) intravenous dose | ChEMBL. | 8064808 |
Duration (functional) | > 24 hr | Time from onset of action until significant (i.e., >=30%) inhibition of pressor response is no longer observed, at 3 (mg/kg) peroral dose | ChEMBL. | 8064808 |
IC50 (binding) | = 0.36 nM | In vitro inhibitory activity against angiotensin II rabbit aorta AT1 receptor using radioligand [125I]-Sar Ile-AII | ChEMBL. | 8064808 |
IC50 (binding) | = 0.36 nM | In vitro inhibitory activity against angiotensin II rabbit aorta AT1 receptor using radioligand [125I]-Sar Ile-AII | ChEMBL. | 8064808 |
IC50 (binding) | = 910 nM | In vitro inhibitory activity against angiotensin II rat midbrain AT2 receptor using radioligand [125I]-Sar Ile-AII | ChEMBL. | 8064808 |
IC50 (binding) | = 910 nM | In vitro inhibitory activity against angiotensin II rat midbrain AT2 receptor using radioligand [125I]-Sar Ile-AII | ChEMBL. | 8064808 |
Inhibition (functional) | = 67 % | Inhibition of AII pressor response by the compound in conscious, normotensive rats, at 1 (mg/kg) intravenous dose | ChEMBL. | 8064808 |
Inhibition (functional) | = 76 % | Inhibition of AII pressor response by the compound in conscious, normotensive rats, at 3 (mg/kg) peroral dose | ChEMBL. | 8064808 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.